#United States #Stratford #KUBTEC #XCELL #TomoRad

KUBTEC® Scientific Unveils XCELL® TomoRad™ for Preclinical Cancer Research

In a groundbreaking moment for cancer research, KUBTEC® Scientific has officially introduced its innovative XCELL® TomoRad™ system at the annual meeting of the American Association of Cancer Researchers (AACR). This state-of-the-art device marks a significant advancement in the field of image-guided radiotherapy (IGRT), redefining how researchers can utilize targeted radiation in their studies.

Transformative Imaging Technology

The XCELL TomoRad™ stands apart with its proprietary tomosynthesis technique. This advanced method captures multiple X-ray images from varying angles to create a detailed three-dimensional representation of the target area. This approach not only provides superior imaging but also reduces radiation exposure for samples, speeding up both image acquisition and reconstruction processes. Compared to traditional microCT imaging, researchers will benefit from increased efficiency and significantly lower costs.

Prior to this, IGRT-capable systems came with high financial barriers, often due to their complex installation and usage. This limitation hindered many researchers from integrating targeted radiation into preclinical animal studies, forcing them to rely on broad-spectrum radiation approaches. Recognizing this need for accessibility, the team at KUBTEC set out to develop the TomoRad to make IGRT research feasibly available to a wider range of laboratories.

Redefining Research Accessibility

Equipped with Advanced Treatment Planning software, TomoRad makes it easier than ever for researchers to access tools needed for precision radiation dosing. The device not only simplifies the setup process but also allows for customizable and repeatable radiation delivery, reducing the time and training required for mastery of the system.

Speed is a critical advantage of the TomoRad. With the unique Mag Mode™—a patent-pending technology—treatments are delivered at lightning speed. This method enables positioning samples optimally near the radiation source, ensuring maximum dosage in minimal time, all while avoiding the considerable expense and space requirements of proton beam systems. This efficiency is crucial for busy laboratories aiming to minimize anesthesia time and alleviate stress for research animals during procedures.

KUBTEC’s Global Sales Director, Shane Smithee, highlighted the feedback from the research community, stating, "Researchers want to streamline their workflows without compromising on study quality. The XCELL TomoRad™ meets this demand, making advanced radiation systems accessible and less daunting."

In a similar vein, KUBTEC CEO Vikram Butani articulated the vision behind this innovation. He noted that traditionally, the high cost and slow performance of IGRT systems barred many researchers from accessing the technology necessary for effective studies. By addressing these obstacles, KUBTEC aims to facilitate research that could lead to improved patient care outcomes in clinical settings.

Commitment to Innovation

KUBTEC® Scientific has been a pioneer in X-ray imaging and irradiation technology for over 20 years, continuously developing transformative tools that empower research in various fields, including preclinical medicine and agriculture. Their comprehensive range of products includes renowned technologies like Image Blender® and DIGISEED®, catering to both the demands of academic research and agricultural innovation.

The introduction of the XCELL® TomoRad™ represents a noteworthy step forward in supporting researchers in their quest to explore new treatments and methodologies, potentially translating into better care for cancer patients in clinical settings.

For further details about the XCELL® TomoRad™ and its capabilities, visit the official KUBTEC Scientific website. This launch is not just about technology; it signifies hope for the future of cancer research and treatment innovation.